In FDA Appeal, Genentech Proposes Biomarker Strategy to Keep Avastin Available for Best Responders | GenomeWeb

Originally published Jan. 23.

By Turna Ray

In appealing
the US Food and Drug Administration's decision to pull Avastin off the market as a treatment for metastatic breast cancer, Genentech has raised the possibility of conducting biomarker analysis to "clarify the clinical benefit" of the drug in patients with high levels of VEGF-A.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In PNAS this week: diatom genetic diversity, microfluidic droplet method for single-cell screening, and more.

Scientific publishers are looking into whether artificial intelligence can help the peer-review process, Wired reports.

Researchers are using gene editing to develop more robust livestock and crops, AFP reports.

Researchers rally near the American Association for the Advancement of Science annual meeting in Boston.